MONTREAL, QUEBEC--(MARKET WIRE)--Jul 16, 2007 -- IBEX Technologies Inc. (Toronto:IBT.TO - News) today announced that it has completed its fifth and final payment to former HDM Diagnostics & Imaging Inc. ("HDM") shareholders to retain the exclusive rights to its portfolio of arthritis biomarkers. In fulfilling its final payment, IBEX issued 1,633,186 common shares, valued at $200,000 (as at July 13, 2007). After giving effect to the fifth-year payment to former HDM shareholders, there are now 24,703,244 common shares of IBEX issued and outstanding.
